|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7666400B2
(en)
*
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US7550143B2
(en)
*
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
ATE516820T1
(de)
|
2000-09-29 |
2011-08-15 |
Schering Corp |
Pegyliertes interleukin 10
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US7906118B2
(en)
*
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8003111B2
(en)
*
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
ES2829566T3
(es)
|
2005-03-03 |
2021-06-01 |
Immunomedics Inc |
Anticuerpos L243 humanizados
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
CA2604032C
(en)
*
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US7855279B2
(en)
*
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
*
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
AU2007343610C1
(en)
*
|
2007-01-17 |
2013-11-07 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
AU2008275911A1
(en)
*
|
2007-07-19 |
2009-01-22 |
Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University |
Self- anchoring MEMS intrafascicular neural electrode
|
|
MX2010001684A
(es)
*
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
CN102186499B
(zh)
*
|
2008-08-20 |
2015-05-20 |
Ibc医药公司 |
用于癌症治疗的对接和锁定(dnl)疫苗
|
|
EP3348281B1
(en)
|
2008-12-17 |
2023-07-05 |
Merck Sharp & Dohme Corp. |
Mono- and di-peg il-10 production; and uses
|
|
US8680050B2
(en)
*
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
CN108530543B
(zh)
|
2009-02-03 |
2023-06-23 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
|
JP5839597B2
(ja)
*
|
2009-06-08 |
2016-01-06 |
アムニクス オペレーティング インコーポレイテッド |
グルコース調節ポリペプチド並びにその作成及び使用方法
|
|
US9849188B2
(en)
|
2009-06-08 |
2017-12-26 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
CN102741275B
(zh)
|
2009-08-24 |
2016-08-03 |
阿穆尼克斯运营公司 |
凝血因子ix组合物及其制备和使用方法
|
|
CN102596235A
(zh)
*
|
2009-08-31 |
2012-07-18 |
免疫医疗公司 |
显示有效细胞毒活性的包含豹蛙酶(rap)的免疫毒素的组合物和使用方法
|
|
CN102481348A
(zh)
*
|
2009-08-31 |
2012-05-30 |
Ibc药品公司 |
双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途
|
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
AU2010315432A1
(en)
*
|
2009-11-05 |
2012-04-12 |
Center For Molecular Medicine And Immunology |
Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
|
|
EP2506881B1
(en)
|
2009-12-02 |
2024-03-06 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
|
EP2509630A4
(en)
*
|
2009-12-09 |
2013-07-17 |
Immunomedics Inc |
SYSTEM FOR PROCESSING CYTOTOXIC REMEDIES THROUGH BISPECIFIC ANTIBODY TARGET
|
|
WO2011072114A1
(en)
*
|
2009-12-09 |
2011-06-16 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) complexes for delivery of interference rna
|
|
EP2518078B1
(en)
*
|
2009-12-15 |
2020-05-20 |
Choe, Muhyeon |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers
|
|
US10822396B2
(en)
|
2009-12-15 |
2020-11-03 |
MuHyeon CHOE |
Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
|
|
US8557961B2
(en)
|
2010-04-02 |
2013-10-15 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
EP2605788B1
(en)
*
|
2010-08-17 |
2018-10-10 |
IBC Pharmaceuticals, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
AU2011323354B2
(en)
*
|
2010-11-03 |
2014-07-31 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
CA2832443C
(en)
|
2011-04-06 |
2020-08-25 |
The Board Of Regents Of The University Of Texas System |
Modulating bacterial mam polypeptides in pathogenic disease
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
US20130101664A1
(en)
|
2011-08-18 |
2013-04-25 |
Donald W. Kufe |
Muc1 ligand traps for use in treating cancers
|
|
EP2753644A1
(en)
|
2011-09-09 |
2014-07-16 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
|
WO2013082254A1
(en)
|
2011-12-02 |
2013-06-06 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
|
|
LT3564260T
(lt)
|
2012-02-15 |
2023-01-10 |
Bioverativ Therapeutics Inc. |
Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
CA2865578C
(en)
|
2012-02-27 |
2023-01-17 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
|
ES2672974T3
(es)
|
2012-06-01 |
2018-06-19 |
Ibc Pharmaceuticals, Inc. |
Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
|
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
KR101358330B1
(ko)
|
2012-09-26 |
2014-02-12 |
현대모비스 주식회사 |
차속 제어 장치, 이를 포함하는 차속 제어 시스템 및 그 제어 방법
|
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
AU2013360335B2
(en)
|
2012-12-13 |
2017-12-07 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
WO2014164394A1
(en)
|
2013-03-11 |
2014-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics
|
|
CN105209054A
(zh)
*
|
2013-04-18 |
2015-12-30 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
JP2016528879A
(ja)
|
2013-06-17 |
2016-09-23 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
タンパク質の同一性および安定性を評価する方法
|
|
TWI667255B
(zh)
|
2013-08-14 |
2019-08-01 |
美商生物化學醫療公司 |
因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
|
|
HK1226308A1
(zh)
|
2013-08-30 |
2017-09-29 |
Armo Biosciences, Inc. |
使用白细胞介素-10治疗疾病和病症的方法
|
|
CA2924520C
(en)
|
2013-11-01 |
2023-09-26 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
|
|
US11413332B2
(en)
|
2013-11-11 |
2022-08-16 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
JP2017509587A
(ja)
|
2013-12-27 |
2017-04-06 |
ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． |
エトキシル化界面活性剤
|
|
US10605810B2
(en)
*
|
2013-12-30 |
2020-03-31 |
University-Industry Cooperation Group Of Kyung Hee University |
Pincers comprising antibody and aptamer conjugated via a linker which binds to the same target material and use thereof
|
|
SG11201605242YA
(en)
|
2014-01-10 |
2016-07-28 |
Biogen Ma Inc |
Factor viii chimeric proteins and uses thereof
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
EP3160504B1
(en)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
SI3204018T1
(sl)
|
2014-10-07 |
2021-11-30 |
Immunomedics, Inc. |
Neoadjuvantna uporaba konjugatov protitelo-zdravilo
|
|
KR20170068553A
(ko)
|
2014-10-14 |
2017-06-19 |
아르모 바이오사이언시스 인코포레이티드 |
인터류킨-15 조성물 및 이의 용도
|
|
JP6675394B2
(ja)
|
2014-10-22 |
2020-04-01 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害の治療のためにインターロイキン−１０を使用する方法
|
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
|
MX391071B
(es)
*
|
2015-03-11 |
2025-03-21 |
Nektar Therapeutics |
Conjugados de un resto de il-7 y un polímero.
|
|
US9797907B2
(en)
|
2015-04-22 |
2017-10-24 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
US20160361415A1
(en)
|
2015-05-28 |
2016-12-15 |
Armo Biosciences, Inc. |
Methods of Using Interleukin-10 for Treating Diseases and Disorders
|
|
CN107614515B
(zh)
|
2015-05-28 |
2022-03-22 |
免疫医疗公司 |
用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
|
|
AU2016281622C1
(en)
|
2015-06-25 |
2021-11-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
IL257231B
(en)
|
2015-08-03 |
2022-09-01 |
Bioverativ Therapeutics Inc |
Factor ix fusion proteins and methods of making and using same
|
|
JP7053453B2
(ja)
|
2015-08-25 |
2022-04-12 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を治療するためのインターロイキン１０の使用方法
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
KR102739782B1
(ko)
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
US12158399B2
(en)
|
2016-08-05 |
2024-12-03 |
Duke University |
CaMKK2 inhibitor compositions and methods of using the same
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
CN110352201A
(zh)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
用于癌症疗法的抗体药物缀合物的皮下施用
|
|
CN107118269B
(zh)
*
|
2017-06-05 |
2020-12-01 |
北京交通大学 |
一种重组人il-24蛋白的peg修饰方法
|
|
US10584306B2
(en)
|
2017-08-11 |
2020-03-10 |
Board Of Regents Of The University Of Oklahoma |
Surfactant microemulsions
|
|
US12037382B2
(en)
|
2018-02-05 |
2024-07-16 |
Stichting Vu |
Inverse agonistic anti-US28 antibodies
|
|
US12281171B2
(en)
|
2018-03-19 |
2025-04-22 |
Bio Ventures, Llc |
Periostin antibodies and methods of using the same
|
|
SI3793588T1
(sl)
|
2018-05-18 |
2025-07-31 |
Bioverativ Therapeutics Inc. |
Postopki zdravljenja hemofilije A
|
|
WO2019227022A1
(en)
|
2018-05-25 |
2019-11-28 |
Bioventures, Llc |
Myxoma virus compositions and methods of use
|
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
|
WO2020106880A1
(en)
|
2018-11-20 |
2020-05-28 |
Bioventures, Llc |
Cells for the production of viruses and methods of using the same
|
|
WO2021021605A1
(en)
|
2019-07-26 |
2021-02-04 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
|
MX2022011892A
(es)
|
2020-03-26 |
2022-10-18 |
Univ Vanderbilt |
Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
EP4408468A4
(en)
|
2021-09-28 |
2025-07-02 |
Frontaim Biomedicines Inc |
MULTIPLE FORMATS OF MOLECULAR COMPLEXES
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|